Please use this identifier to cite or link to this item:
Title: Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
Author: Mesquita, Fernanda Cristina de
Guixé Muntet, Sergi
Fernández Iglesias, Anabel
Maeso Díaz, Raquel
Vila, Sergi
Hide Alférez, Diana
Ortega Ribera, Martí
Rosa López, José Luis
García Pagán, Juan Carlos
Bosch i Genover, Jaume
Oliveira, Jarbas Rodrigues de
Gracia-Sancho, Jorge
Keywords: Cirrosi hepàtica
Malalties del fetge
Hepatic cirrhosis
Liver diseases
Issue Date: 12-Jun-2017
Publisher: Nature Publishing Group
Abstract: Hepatic stellate cells (HSC) play a key role in the development of chronic liver disease (CLD). Liraglutide, well-established in type 2 diabetes, showed anti-inflammatory and anti-oxidant properties. We evaluated the effects of liraglutide on HSC phenotype and hepatic microvascular function using diverse pre-clinical models of CLD. Human and rat HSC were in vitro treated with liraglutide, or vehicle, and their phenotype, viability and proliferation were evaluated. In addition, liraglutide or vehicle was administered to rats with CLD. Liver microvascular function, fibrosis, HSC phenotype and sinusoidal endothelial phenotype were determined. Additionally, the effects of liraglutide on HSC phenotype were analysed in human precision-cut liver slices. Liraglutide markedly improved HSC phenotype and diminished cell proliferation. Cirrhotic rats receiving liraglutide exhibited significantly improved liver microvascular function, as evidenced by lower portal pressure, improved intrahepatic vascular resistance, and marked ameliorations in fibrosis, HSC phenotype and endothelial function. The anti-fibrotic effects of liraglutide were confirmed in human liver tissue and, although requiring further investigation, its underlying molecular mechanisms suggested a GLP1-R-independent and NF-κB-Sox9-dependent one. This study demonstrates for the first time that liraglutide improves the liver sinusoidal milieu in pre-clinical models of cirrhosis, encouraging its clinical evaluation in the treatment of chronic liver disease.
Note: Reproducció del document publicat a:
It is part of: Scientific Reports, 2017, vol. 7, num. 3255
Related resource:
ISSN: 2045-2322
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
673333.pdf1.84 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons